Stock Taper
PULM
PULMATRIX, INC.
NASDAQ
$1.50
▼ DOWN 0.33% (-0.01)

KEY STATISTICS

Market Cap$5.46 M
52w High$5.50
52w Low$1.16
Dividend Yield
Frequency
P/E-1.36
Volume39.61K
Shares Out.3.65M

COMPANY

LEADERSHIP

Peter Ludlum
CHIEF EXECUTIVE
Peter Ludlum

COMPENSATION 2026

Salary$567,294
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$10,422
Total$691,888

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 21, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
2

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.53M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2022-03-01Reverse1:20
2019-02-06Reverse1:10
2015-06-16Reverse2:5

PRICE

$1.50 ▼ DOWN 0.33% (−$0.01)
OVERLAYS
$1.48$1.50$1.5210:20 AM11:17 AM12:13 PM1:09 PM2:06 PM3:03 PM3:59 PM1.50

About Pulmatrix, Inc.

https://www.pulmatrix.com ↗

Pulmatrix, Inc. is a biotech company developing inhaled therapies using iSPERSE technology for respiratory and other diseases, with products like Pulmazole, PUR1800, and PUR3100 in various clinical stages.

INDUSTRY

Biotechnology

A PRODUCT PULMATRIX, INC. IS KNOWN FOR

PUR3100
PUR3100

PUR3100 is a Phase 2-ready, inhaled dry powder dihydroergotamine (DHE) for acute migraine treatment, utilizing Pulmatrix's proprietary iSPERSE™ technology.

Revenue by Products

IconPRODUCTQ2-2015Q3-2015Q4-2015
Tiotropium Bromide Collaboration Agreement$170K $651K
Material Transfer Agreement$39K $38K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score2

SECTORS PEERS

PEERPRICE
PALI$2.10COMPARE
LGVN$0.84COMPARE
DARE$0.82COMPARE
CTXR$0.60COMPARE
ADTX$0.01COMPARE
CRIS$1.58COMPARE
FBLG$1.44COMPARE
ASBP$7.97COMPARE